Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Uncover which credit cards provide rewards miles with no annual fee. Make the most of your spending and earn rewards.
24,553 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A fresh Miladys loyalty pledge stirs controversy in the Ethereum community, pitting branding loyalties against core p...
Amazon launches a $200 billion AI-focused capex plan for 2026, with Trainium and Anthropic in the mix. Here’s what in...
A new Grok AI forecast signals a measured gain for Bitcoin, Ethereum, and XRP through May 2026, with upside contingen...
Celanese (CE) stands at an inflection point as 2026 begins. This article breaks down the potential drivers behind cel...
Many investors chase headline names, but a quiet stock nobody's talking about could surge as AI, data, and systems de...
An AI-led forecast suggests ripple (xrp) price prediction could push XRP to $500 by 2035, renewing debates about the ...
Sandisk has surged as AI infrastructure gains grab headlines. But can the rally last? This article lays out 3-year sc...
Apyx Medical (APYX) 2026 is shaping up as a pivotal year for investors. This guide breaks down how to read the Q1 tra...
A leading economist argues that recessions aren’t predictable cycles after studying four centuries of data, urging ho...
A controlled study finds women face harsher judgments when AI helps craft resumes, while men's resumes win quicker ap...
With Trump heading to China for high-stakes talks, Goldman Sachs flags a dollar overvaluation of roughly 12-15% versu...